Integrated Blood Pressure Control

metrics 2024

Empowering Cardiovascular Insights for All

Introduction

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

Metrics 2024

SCIMAGO Journal Rank0.58
Journal Impact Factor1.50
Journal Impact Factor (5 years)2.80
H-Index28
Journal IF Without Self1.50
Eigen Factor0.00
Normal Eigen Factor0.08
Influence0.75
Immediacy Index0.60
Cited Half Life5.70
Citing Half Life6.20
JCI0.40
Total Documents131
WOS Total Citations337
SCIMAGO Total Citations962
SCIMAGO SELF Citations15
Scopus Journal Rank0.58
Cites / Document (2 Years)1.61
Cites / Document (3 Years)2.34
Cites / Document (4 Years)2.92

Metrics History

Rank 2024

Scopus

Cardiology and Cardiovascular Medicine in Medicine
Rank #136/387
Percentile 64.86
Quartile Q2
Internal Medicine in Medicine
Rank #66/167
Percentile 60.48
Quartile Q2

IF (Web Of Science)

PERIPHERAL VASCULAR DISEASE
Rank 67/96
Percentile 30.70
Quartile Q3

JCI (Web Of Science)

PERIPHERAL VASCULAR DISEASE
Rank 62/96
Percentile 35.42
Quartile Q3

Quartile History

Similar Journals

Blood and Lymphatic Cancer-Targets and Therapy

Transforming Cancer Treatment Through Open Access
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Clinical Hypertension

Shedding light on breakthroughs in hypertension management.
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

ARYA Atherosclerosis

Bridging gaps in atherosclerosis research for global impact.
Publisher: ISFAHAN UNIV MEDICAL SCIENCES, ISFAHAN CARDIOVASCULAR RES CENTERISSN: 1735-3955Frequency: 4 issues/year

ARYA Atherosclerosis is a distinguished open-access journal published by Isfahan University of Medical Sciences and the Isfahan Cardiovascular Research Center, with an ISSN of 1735-3955 and an E-ISSN of 2251-6638. Founded in 2005, this journal seeks to advance the field of cardiology and cardiovascular medicine by providing a platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings related to atherosclerosis and its implications for cardiovascular health. Although currently ranked in Q4 of its category in 2023, ARYA Atherosclerosis plays a vital role in the academic community by promoting open access to vital research, fostering collaboration, and encouraging the sharing of knowledge. The journal's commitment to transparency and accessibility makes it an essential resource for those looking to stay informed about the latest developments in cardiovascular research. Based in Iran, it is positioned within an emerging research landscape that is increasingly contributing to global health discussions.

Rational Pharmacotherapy in Cardiology

Advancing Cardiovascular Care through Evidence-Based Pharmacotherapy
Publisher: SOC CARDIOLOGY RUSSIAN FEDERATISSN: 1819-6446Frequency: 6 issues/year

Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.

JOURNAL OF HUMAN HYPERTENSION

Pioneering research that bridges science and clinical practice.
Publisher: SPRINGERNATUREISSN: 0950-9240Frequency: 12 issues/year

JOURNAL OF HUMAN HYPERTENSION, a prominent publication in the field of internal medicine, is dedicated to advancing the understanding of hypertension and its implications for human health. Published by SPRINGERNATURE in the United Kingdom, this esteemed journal has been a vital resource for researchers and clinicians since its inception in 1987, with a continuous commitment to disseminating high-quality, peer-reviewed research. With an impressive Q2 category rank in Internal Medicine and a Scopus rank of 53 out of 167, it occupies a crucial position within the academic community, reaching a 68th percentile ranking that underscores its significance. The journal aims to provide a platform for innovative studies and reviews, fostering knowledge that bridges basic science, clinical practice, and public health. Although it does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital information about hypertension is available to a broad spectrum of healthcare professionals and researchers. Explore the critical findings and groundbreaking research published in the JOURNAL OF HUMAN HYPERTENSION to stay at the forefront of hypertension studies.

Journal of Atherosclerosis and Thrombosis

Advancing cardiovascular knowledge for a healthier future.
Publisher: JAPAN ATHEROSCLEROSIS SOCISSN: 1340-3478Frequency: 12 issues/year

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

COR ET VASA

Bridging the gap between research and clinical practice in cardiology.
Publisher: CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERYISSN: 0010-8650Frequency: 6 issues/year

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

Journal of Cardiology

Connecting researchers and clinicians in the fight against heart disease.
Publisher: ELSEVIERISSN: 0914-5087Frequency: 12 issues/year

Journal of Cardiology, published by ELSEVIER, stands as a prominent resource in the field of cardiology and cardiovascular medicine. With a rich history since its inception in 1987, this peer-reviewed journal aims to disseminate cutting-edge research that enhances the understanding and treatment of cardiovascular diseases. Its 2023 ranking places it in the Q2 category within its discipline, reflecting its significance and impact, as evidenced by a Scopus rank of #123 out of 387 journals, positioning it in the 68th percentile of its field. The journal is headquartered in Japan, providing a unique perspective on cardiological advances relevant not only to the Asian continent but also globally. Though it does not currently offer open access, the Journal of Cardiology remains a vital institutional resource for researchers, clinicians, and students seeking to push the boundaries of cardiovascular science and improve patient outcomes.

Acta Cardiologica Sinica

Elevating Cardiology Research to New Heights.
Publisher: TAIWAN SOC CARDIOLOGYISSN: 1011-6842Frequency: 4 issues/year

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

Netherlands Heart Journal

Uniting Researchers to Revolutionize Cardiovascular Care
Publisher: BOHN STAFLEU VAN LOGHUM BVISSN: 1568-5888Frequency: 12 issues/year

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.